image: Delivering the latest industry insight into innovative early-stage research, techniques, and tools for optimizing new pharmaceutical development.
Credit: Mary Ann Liebert, Inc.
New Rochelle, NY, October 17, 2025—Mary Ann Liebert, Inc., is pleased that Wai Hong (Kevin) Lo, PhD, has been appointed the new Editor-in-Chief of the journal ASSAY and Drug Development Technologies. Dr. Lo is replacing Bruce Melancon, PhD as Editor-in-Chief.
ASSAY and Drug Development Technologies provides access to novel techniques and robust tools that enable critical advances in early-stage screening. This research published in the Journal leads to important therapeutics and platforms for drug discovery and development. This peer-reviewed journal features original papers application-oriented technology reviews, topical issues on novel and burgeoning areas of research, and reports in methodology and technology application.
“It has been an honor and a pleasure to serve as Editor-in-Chief of ASSAY and Drug Development Technologies these past few years. I am delighted to pass the baton to Dr. Lo, who I’m certain will take the journal to new heights,” said Dr. Melancon.
“My vision for ASSAY and Drug Development Technologies is to create a platform that genuinely represents diverse voices in authorship, readership, and editorial contributions, while maintaining its leadership in the field. I plan to introduce innovative approaches, such as enhancing online accessibility, incorporating visuals and lay summaries, and increasing social media engagement. These efforts will help us reach a broader audience, making our content more engaging and relevant to diverse scientific and industrial communities. I am excited to take on the role of Editor-in-Chief and lead these initiatives forward,” said Dr. Lo.
Dr. Lo is an accomplished biotechnology researcher and translational scientist with over 20 years of experience. As an Associate Professor at the University of Connecticut Health Center, his research expertise includes tissue regenerative engineering, biochemistry, cell signaling studies, biomaterials development, animal models, and drug discovery and delivery. His research programs have been continuously funded by federal agencies such as the National Institutes of Health. Dr. Lo has a remarkable editorial track record. He serves as the founding Deputy Editor of the Journal of Racial and Ethnic Health Disparities, where he played a pivotal role in establishing its prominence in the field. Additionally, he serves as an Associate Editor for PLoS ONE and Frontiers in Bioengineering and Biotechnology and is on the editorial boards of prestigious journals such as Scientific Reports, Biomedicines, and Regenerative Engineering and Translational Medicine.
Mary Ann Liebert, Inc., would like to thank Dr. Melancon for his dedication and service to the journal.
About the Journal
ASSAY and Drug Development Technologies is an international pharmaceutical science journal dedicated to the publication of innovative research, scientific reviews, and academic communications pertaining to all aspects of innovative early-stage research, techniques, and tools for optimizing new pharmaceutical development. Tables of content and a free sample issue may be viewed on the ASSAY and Drug Development Technologies website.
About the Publisher
Mary Ann Liebert, Inc., publishers is a global media company dedicated to creating, curating, and delivering impactful peer-reviewed research and authoritative content services to advance the fields of biotechnology and the life sciences, specialized clinical medicine, and public health and policy. For complete information, please visit the Mary Ann Liebert, Inc., publishers website.
Journal
Assay and Drug Development Technologies